Antimicrobial resistance (AMR) is one of the most pressing global healthcare challenges, creating an urgent need for innovative anti-infective therapies that can address pathogens resistant to existing treatments. Among these, methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of both community- and healthcare-associated infections and is recognized by the World Health Organization as a high-priority antimicrobial-resistant pathogen requiring continued research and drug development efforts. 

Evotec's In Vivo Pharmacology team provides deep expertise in the development and execution of clinically relevant infectious disease models to support anti-infective drug discovery and translational research. Our experts work closely with partners to design customized in vivo studies that enable robust assessment of novel therapeutic approaches against challenging bacterial pathogens.

This publication highlights the successful application of a bespoke MRSA skin infection model to evaluate Epidermicin NI01, a first-in-class bacteriocin with a novel mechanism of action. The study demonstrates how advanced in vivo models can generate critical efficacy data for emerging therapeutic modalities and support the development of innovative alternatives to conventional antibiotics in the fight against antimicrobial resistance.

Read the publication to learn how Evotec's infectious disease and in vivo pharmacology expertise can help accelerate the discovery and development of next-generation anti-infective therapies.